Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07225504 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
A Phase 3 study of Secondary Progressive Multiple Sclerosis (SPMS), sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,275
- Enrollment target
- 20
- Study locations
NCT07225504 is a Phase 3 study of Secondary Progressive Multiple Sclerosis (SPMS) that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 1,275 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT07225504, a Phase 3 study of Secondary Progressive Multiple Sclerosis (SPMS), is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,275 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Remibrutinib (blinded)
- DRUG Remibrutinib (Open label)
Study Locations (20)
Florida
- Neurology of Central FL Res Ctr - Altamonte Springs
- Aqualane Clinical Research - Naples
- Orlando Health Clinical Trials - Orlando
- Neurology Associates of Ormond Beach - Ormond Beach
- Axiom Brain Health - Tampa
California
- Fullerton Neuro and Headache Ctr - Fullerton
- Regina Berkovich MD PhD Inc - West Hollywood
New South Wales
- Novartis Investigative Site - Kogarah
- Novartis Investigative Site - Westmead
Victoria
- Novartis Investigative Site - Clayton
- Novartis Investigative Site - Heidelberg
Alabama
- Alabama Neurology Associates PC - Birmingham
Arizona
- AZ Integrated Neuro and Spine - Phoenix
Hawaii
- Hawaii Pacific Neuroscience LLC - Honolulu
Kansas
- University of Kansas Hospital - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,275 participants |
| Start Date | 2025-11-11 |
| Est. Completion | 2034-01-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07225504
The ClinicalTrials.gov registry entry for NCT07225504 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Secondary Progressive Multiple Sclerosis (SPMS) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07225504 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, New South Wales.
Frequently Asked Questions
What is clinical trial NCT07225504 about?
NCT07225504 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis". The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
What is the current status of trial NCT07225504?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,275 participants. The study started on 2025-11-11. Estimated completion is 2034-01-02.
What conditions does trial NCT07225504 study?
This clinical trial studies the following conditions: Secondary Progressive Multiple Sclerosis (SPMS).
What interventions are being tested in trial NCT07225504?
The interventions under investigation include: Placebo (DRUG), Remibrutinib (blinded) (DRUG), Remibrutinib (Open label) (DRUG).
Who is sponsoring clinical trial NCT07225504?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07225504 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Progressive Multiple Sclerosis (SPMS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.